
    
      The trial will recruit 184 patients, and they will be randomized (1:1) into two groups
      (radiotherapy+anti-PD-1 group, gemcitabine+cisplatin group). Patients in
      radiotherapy+anti-PD-1 group will receive conventional intensity-modulated radiotherapy or
      stereotactic body radiation therapy first for a total dose more than 40Gy. Camrelizumab 200mg
      intravenously every 3 weeks will be initiated within 7 days after radiotherapy. Patients in
      chemotherapy group will receive cisplatin 25mg/m2 intravenously (day 1 and day 8) and then
      gemcitabine 1000mg/m2 intravenously (day 1 and day 8) every 3 weeks (1 cycle), for 8 cycles.
    
  